Wedbush Comments on IGM Biosciences, Inc.’s Q2 2025 Earnings (NASDAQ:IGMS)

IGM Biosciences, Inc. (NASDAQ:IGMS) – Equities researchers at Wedbush issued their Q2 2025 earnings per share (EPS) estimates for IGM Biosciences in a research report issued to clients and investors on Tuesday, October 1st. Wedbush analyst R. Driscoll forecasts that the company will post earnings per share of ($0.38) for the quarter. Wedbush currently has a “Outperform” rating and a $22.00 target price on the stock. The consensus estimate for IGM Biosciences’ current full-year earnings is ($3.13) per share. Wedbush also issued estimates for IGM Biosciences’ Q3 2025 earnings at ($0.40) EPS and Q4 2025 earnings at ($0.40) EPS.

A number of other equities analysts also recently commented on the company. Guggenheim dropped their price objective on IGM Biosciences from $25.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday. JPMorgan Chase & Co. downgraded IGM Biosciences from a “neutral” rating to an “underweight” rating and decreased their price target for the stock from $12.00 to $9.00 in a research note on Tuesday. HC Wainwright cut their price objective on IGM Biosciences from $12.00 to $11.00 and set a “neutral” rating on the stock in a research note on Thursday, September 5th. Truist Financial cut IGM Biosciences from a “buy” rating to a “hold” rating and decreased their target price for the stock from $24.00 to $12.00 in a research report on Tuesday. Finally, Royal Bank of Canada lowered their target price on shares of IGM Biosciences from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Tuesday. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $14.67.

IGM Biosciences Price Performance

Shares of NASDAQ IGMS opened at $14.90 on Wednesday. IGM Biosciences has a one year low of $3.81 and a one year high of $22.50. The business’s 50-day moving average price is $11.75 and its two-hundred day moving average price is $9.82. The company has a market capitalization of $879.46 million, a P/E ratio of -3.46 and a beta of 0.21.

IGM Biosciences (NASDAQ:IGMS) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of $0.18 by ($0.97). IGM Biosciences had a negative return on equity of 119.02% and a negative net margin of 7,571.35%. The company had revenue of $1.25 million for the quarter, compared to analyst estimates of $51.75 million.

Insider Buying and Selling at IGM Biosciences

In related news, CEO Fred Schwarzer sold 3,946 shares of the firm’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $11.54, for a total value of $45,536.84. Following the completion of the transaction, the chief executive officer now directly owns 250,124 shares of the company’s stock, valued at $2,886,430.96. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other IGM Biosciences news, CEO Fred Schwarzer sold 3,946 shares of the firm’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $11.54, for a total transaction of $45,536.84. Following the completion of the transaction, the chief executive officer now owns 250,124 shares in the company, valued at $2,886,430.96. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Julie Hambleton sold 15,132 shares of IGM Biosciences stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $14.00, for a total value of $211,848.00. Following the sale, the director now directly owns 2,000 shares in the company, valued at $28,000. The disclosure for this sale can be found here. Insiders sold a total of 21,034 shares of company stock valued at $279,957 in the last quarter. Corporate insiders own 57.00% of the company’s stock.

Institutional Investors Weigh In On IGM Biosciences

Several large investors have recently made changes to their positions in the company. Quest Partners LLC increased its holdings in IGM Biosciences by 71.4% during the 2nd quarter. Quest Partners LLC now owns 11,913 shares of the company’s stock valued at $82,000 after purchasing an additional 4,961 shares in the last quarter. AQR Capital Management LLC bought a new position in shares of IGM Biosciences in the second quarter valued at about $84,000. EntryPoint Capital LLC bought a new position in shares of IGM Biosciences in the first quarter valued at about $152,000. XTX Topco Ltd grew its holdings in IGM Biosciences by 70.9% during the 2nd quarter. XTX Topco Ltd now owns 20,408 shares of the company’s stock worth $140,000 after acquiring an additional 8,467 shares during the last quarter. Finally, Rhumbline Advisers grew its holdings in IGM Biosciences by 13.1% during the 2nd quarter. Rhumbline Advisers now owns 22,726 shares of the company’s stock worth $156,000 after acquiring an additional 2,635 shares during the last quarter. Institutional investors own 42.79% of the company’s stock.

IGM Biosciences Company Profile

IGM Biosciences, Inc, a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases.